Targeting the CXCL1-CXCR2 chemotactic pathway presents a potential immunotherapeutic strategy to impede the advancement of RIP3-deficient HCC (48).In H22 orthotopic HCC mice, PMN-MDSCs exhibit increased prevalence compared to M-MDSCs, predominating in the spleen, peripheral blood, and tumor tissue. The gene discussed is CXCR2; the disease is hepatocellular carcinoma.